Direct oral anticoagulants in oncology in clinical praxis
Authors:
Juraj Sokol 1; František Nehaj 2; Marianna Kubašková 3; Michal Mokáň 2; František Kovář 2; Martin Jozef Péč 4; Marián Mokáň 2
Authors place of work:
Klinika hematológie a transfuziológie JLF UK a UNM, Martin, a Národné centrum hemostázy a trombózy UNM, Martin, Slovenská republika
1; I. interná klinika JLF UK a UNM, Martin, Slovenská republika
2; Rádiologická klinika JLF UK a UNM, Martin, Slovenská republika
3; Ústav lekárskej biológie JLF UK v Martine, Slovenská republika
4
Published in the journal:
Vnitř Lék 2019; 65(1): 45-50
Category:
Case reports
Summary
Relation between oncological diseases and venous thrombo-embolism (VTE) is well known for almost 2 centuries. In 1823 Bouillaud assumed by three patients with tumor and recent deep vein thrombosis (DVT), that peripheral edema of lower limbs emerges as a result of „obturation“ of veins by „fibrinous coagulum“ (caillot fibrineux), which was induced by oncological disease. French physician Armand Trousseau wrote about this relation in his book „Phlegmasia alba dolens” again in the year 1865. Many studies were developed in times of Bouillaud a Trousseau, which just confirmed existence of relation between tumor and VTE. Oncological disease presents a significant risk factor of formation of VTE. Recent references favorising the use of light molecular weight heparin (LMWH) in long-term anticoagulation therapy of patients with cancer. Recently we have just few clinical data about efficiency and safety of direct oral anticoagulants (DOACs) in oncological patients, however many meta-analysis of clinical studies has shown benefit of therapy with DOACs towards conventional therapy.
Key words:
direct oral anticoagulants (DOACs) – oncology – venous thromboembolism
Zdroje
- Bouillard JB, Bouillaud S. De l’Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1823; 1: 188–204.
- Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l’Hotel-Dieu de Paris 1865; 3: 654–712.
- Levitan H, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78(5): 285–291.
- Olas B, Mielicki WP, Wachowicz B et al. Cancer procoagulant stimulates platelet adhesion. Thromb Res 1999; 94(3): 199–203.
- Rickles FR, Levine M, Edwards RL. Haemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11(3–4): 237–248.
- Behranwala KA, Williamson RC. Cancer-associated venous thrombosis in the surgical setting. Ann Surg 2009; 249(3): 366–375. Dostupné z DOI: <http://dx.doi.org/10.1097/SLA.0b013e318195c50c>.
- Garcia JG. Molecular mechanisms of thrombin-induced human and bovine endothelial cell activation. J Lab Clin Med 1992; 120(4): 513–519.
- Ravikumar R, Lim CS, Davies AH. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. Adv Exp Med Biol 2017; 906: 137–148. ISBN 978–3-319–22107–6 (print). ISBN 978–3-319–22108–3 (on-line). Dostupné z DOI: <http://dx.doi.org/10.1007/5584_2016_112>.
- Mandala M, Falanga A, Roila F. [ESMO Guidelines Working Group]. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): vi85-vi92. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdr392>.
- Farge D, Debourdeau P, Beckers M et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11(1): 56–70. Dostupné z DOI: http://doi10.1111/jth.12070>.
- Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl): e419S-e494S. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.11–2301>. Erratum in Chest 2012 ;142(6):1698–1704.
- Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33(6): 654–656. Dostupné z DOI: <http:// doi: 10.1200/JCO.2014.59.7351>.
- Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009; 361(24): 2342–2352. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0906598>.
- Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129(7): 764–772. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004450>.
- Baursacher R, Berkowitz SD, Brenner B et al. [EINSTEIN Investigators]. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363(26): 2499–2510. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1007903>.
- Agnelli G, Büller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369(9): 799–808. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1302507>.
- Büller HR, Decousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369(15): 1406–1415. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1306638>. Erratum in N Engl J Med 2014; 370(4): 390.
- Vedovati MC, Germini F, Agnelli G et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147(2): 475–483. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.14–0402>.
- Cohen AT, Spiro TE, Buller HR et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368(6): 513–523. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1111096>.
- Goldhaber SZ, Leizorovicz A, Kakkar AK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365(23): 2167–2177. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1110899>.
- Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293(6): 715–722. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.293.6.715>.
- Kearon C, Akl EA, Ornelas J et al., Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 141(2 Suppl): e419S-e496S. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.11–2301>. Erratum in Chest 2012 ;142(6): 1698–1704.
- Michalcová J, Penka M, Buliková A et al. Nová – přímá perorální antikoagulancia: aktuální přehled. Vnitř Lék 2016; 62(10): 805–813.
- Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146–153. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa025313>.
- Raskob GE, van Es N, Verhamme P et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378(7): 615–624. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1711948>.
- Alikhan R, Cohen AT, Combe S et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14(4): 341–346.
- Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25(34): 5490–5505. Dostupné z DOI: <http://doi 10.1200/JCO.2007.14.1283>.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2019 Číslo 1
Najčítanejšie v tomto čísle
- Diagnostic pitfalls of celiac disease
- Non-celiac gluten/wheat sensitivity: still more questions than answers
- Potential possibility of phosphocreatine usage in internal medicine
- The combination of acromegaly and Klinefelter syndrome in one patient